MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

InVisionFirst plasma-based comprehensive genomic profiling is covered for patients with advanced (Stage IIIB/IV) non-small cell lung cancer when tissue-based CGP is infeasible, specifically at diagnosis if tissue results for EGFR, ALK, ROS1, and BRAF are unavailable, at progression after chemotherapy or immunotherapy when prior genotyping is absent and tissue is infeasible, and for patients progressing on EGFR TKIs. A negative or insufficient ctDNA result should prompt consideration of tissue-based genotyping. Documentation should confirm advanced NSCLC staging, infeasibility of tissue testing (QNS or biopsy contraindication), prior treatments, and prior genotyping status.

"InVisionFirst (Inivata) plasma-based somatic comprehensive genomic profiling is covered for patients with advanced (Stage IIIB/IV) non-small cell lung cancer (NSCLC) at initial diagnosis when resul..."